Supplement Scoop: FDA Wants Your Label Lowdown
Published Date: 2/24/2026
Notice
Summary
The FDA wants to hear from companies that make, package, label, or store dietary supplements about their current manufacturing rules. They’re asking for feedback on how they collect information to make sure supplements are safe and high-quality. If you’re involved in dietary supplements, you’ve got until April 27, 2026, to share your thoughts—no extra costs, just your voice!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Major Recordkeeping Burden for Supplement Makers
Dietary supplement businesses must follow 21 CFR part 111 recordkeeping across many areas (personnel, sanitation, equipment, production controls, quality control, components/packaging, batch records, complaints, etc.). FDA estimates the total annual recordkeeping burden at 929,140 hours (including 279,120 hours for quality control records under §111.140, 279,120 hours for components/packaging records under §111.180, and 204,160 hours for batch production records under §111.260). The Agency also states there are no capital or operating and maintenance costs associated with this collection.
Option to Reduce 100% Ingredient Testing
Under 21 CFR 111.75(a)(1), a manufacturer that currently performs 100% identity testing of incoming dietary ingredients may petition the FDA (under 21 CFR 10.30) to request an exemption to reduce the testing frequency if it demonstrates no material diminution of assurance. FDA estimates the reporting burden for such a petition as 1 response taking 8 hours.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-03588 — Hearing Designation Order Issued to 97.5 Licensee TX, LLC
The FCC is holding a hearing about 97.5 Licensee TX, LLC’s request to transfer control of three El Paso radio stations. They’re checking if the current owner followed the rules, if an unauthorized transfer happened, and if everyone involved is honest and qualified. If you want to join the hearing, you must act by March 26, 2026—this could affect who runs these stations and how they operate.
Next: 2026-03590 — Agency Information Collection Activity Under OMB Review: Bus Testing Program
The Federal Transit Administration is asking for public feedback on its Bus Testing Program paperwork by March 26, 2026. This affects bus manufacturers and testers who provide info to make sure buses are safe and reliable. The goal is to keep the process clear and easy while following government rules—no big cost changes, just smoother info collection.